| Literature DB >> 22485178 |
David A Hysom1, Pejman Naraghi-Arani, Maher Elsheikh, A Celena Carrillo, Peter L Williams, Shea N Gardner.
Abstract
PriMux is a new software package for selecting multiplex compatible, degenerate primers and probes to detect diverse targets such as viruses. It requires no multiple sequence alignment, instead applying k-mer algorithms, hence it scales well for large target sets and saves user effort from curating sequences into alignable groups. PriMux has the capability to predict degenerate primers as well as probes suitable for TaqMan or other primer/probe triplet assay formats, or simply probes for microarray or other single-oligo assay formats. PriMux employs suffix array methods for efficient calculations on oligos 10-~100 nt in length. TaqMan® primers and probes for each segment of Rift Valley fever virus were designed using PriMux, and lab testing comparing signatures designed using PriMux versus those designed using traditional methods demonstrated equivalent or better sensitivity for the PriMux-designed signatures compared to traditional signatures. In addition, we used PriMux to design TaqMan® primers and probes for unalignable or poorly alignable groups of targets: that is, all segments of Rift Valley fever virus analyzed as a single target set of 198 sequences, or all 2863 Dengue virus genomes for all four serotypes available at the time of our analysis. The PriMux software is available as open source from http://sourceforge.net/projects/PriMux.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22485178 PMCID: PMC3317645 DOI: 10.1371/journal.pone.0034560
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Text box listing important aspects of PriMux.
Figure 2Diagram of the PriMux approach.
A subset of the most commonly changed user-specifiable parameters in the options file.
| Selected User Parameters | Meaning |
| maxPolyX | maximum number of homopolymer bases allowed in a primer or probe |
| primer_selection_iterations | number of alternative, non-overlapping primer sets to attempt to find |
| probe_selection_iterations | number of alternative, non-overlapping probes to attempt to find |
| max_mm | maximum allowable number of degenerate bases per primer or probe |
| min_kmer_len | minimum primer or probe length allowed |
| max_kmer_len | maximum primer or probe length allowed |
| min_amplicon_length | minimum amplicon length allowed |
| max_amplicon_length | maximum amplicon length allowed |
| min_hairpin_dG | minimum hairpin free energy allowed |
| min_primer_dimer_dG | minimum free energy of primer dimers (including homodimers) |
| min_tm | minimum Tm allowed of primer or probe |
| max_tm | maximum Tm allowed of primer or probe |
| min_percent_gc | minimum % GC allowed |
| max_percent_gc | maximum % GC allowed |
| min_dist_mm_to_3prime_end | no degenerate bases are allowed closer than this to the 3′ end of a primer or probe |
Figure 3Diagram of the PriMux software workflow.
Rift Valley Fever (RVF) Degenerate Assay Signatures.
| Sig-natureName | Forward PrimerSequence | Reverse PrimerSequence | Probe Name | Conserved Probe Sequence |
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
| |||
|
|
| |||
|
|
|
|
|
|
|
|
| |||
|
|
|
Primer and probe (IO) sequences for RVFV run with all segments in a single input file.
| Forward (F) or Reverse(R) Primer and Probe (IO) | |
| 1|F |
|
| 2|R |
|
| 3|F |
|
| 4|R |
|
| 5|F |
|
| 6|R |
|
| 7|F |
|
| 8|R |
|
| 9|F |
|
| 10|R |
|
| 1|IO |
|
| 2|IO |
|
| 3|IO |
|
| 4|IO |
|
| 5|IO |
|
| 6|IO |
|
| 7|IO |
|
Numbers of RVFV targets detected by each primer/probe combination.
| F | IO | R | # targets detected | % of sequences detected from this segment | segment |
| 1 | 2 | 84 | 100% | S | |
| 1 | 1 | 2 | 83 | 99% | S |
| 1 | 6 | 2 | 65 | 77% | S |
| 3 | 4 | 59 | 98% | M | |
| 9 | 10 | 59 | 98% | M | |
| 9 | 2 | 10 | 58 | 97% | M |
| 3 | 7 | 4 | 53 | 88% | M |
| 9 | 5 | 10 | 50 | 83% | M |
| 5 | 6 | 52 | 96% | L | |
| 5 | 3 | 6 | 52 | 96% | L |
| 7 | 8 | 50 | 93% | L | |
| 7 | 4 | 8 | 29 | 54% | L |
F,P, and IO numbers refer to the sequences in Table 3.
Multiplex set of primers and probes to detect all 2863 Dengue virus genomes.
| 1|F |
|
| 2|R |
|
| 3|F |
|
| 4|R |
|
| 5|F |
|
| 6|R |
|
| 7|F |
|
| 8|R |
|
| 9|F |
|
| 10|R |
|
| 1|IO |
|
| 2|IO |
|
| 3|IO |
|
| 4|IO |
|
| 5|IO |
|
| 6|IO |
|
| 7|IO |
|
| 8|IO |
|
| 9|IO |
|
| 10|IO |
|
| 11|IO |
|
| 12|IO |
|
| 13|IO |
|
| 14|IO |
|
| 15|IO |
|
Primer and probe combinations from Table 5, and number and serotypes of Dengue virus genomes detected by each primer/probe combination.
| FP | IO | RP | # targets detected | Serotypes detected | % of targets detected in indicated serotype(s) |
| 1 | 2 | 2356 | 1–4 | 82% | |
| 1 | 1 | 2 | 2334 | 1–4 | 82% |
| 1 | 7 | 2 | 2329 | 1–4 | 81% |
| 1 | 13 | 2 | 779 | 2 | 88% |
| 1 | 8 | 2 | 80 | 4 | 91% |
| 3 | 4 | 1842 | 1,3 | 98% | |
| 3 | 2 | 4 | 1208 | 1 | 98% |
| 3 | 15 | 4 | 922 | 1 | 75% |
| 3 | 3 | 4 | 627 | 3 | 97% |
| 5 | 6 | 840 | 2 | 95% | |
| 5 | 14 | 6 | 778 | 2 | 88% |
| 5 | 4 | 6 | 554 | 2 | 63% |
| 5 | 12 | 6 | 480 | 2 | 54% |
| 5 | 11 | 6 | 469 | 2 | 53% |
| 5 | 9 | 6 | 447 | 2 | 51% |
| 7 | 8 | 1035 | 1,2 | 49% | |
| 7 | 5 | 8 | 791 | 1 | 64% |
| 7 | 6 | 8 | 42 | 2 | 5% |
| 9 | 10 | 611 | 3 | 95% | |
| 9 | 10 | 10 | 454 | 3 | 70% |
| 3 | 6 | 61 | 2 | 7% | |
| 3 | 12 | 6 | 58 | 2 | 7% |
| 3 | 14 | 6 | 58 | 2 | 7% |
| 3 | 11 | 6 | 57 | 2 | 6% |
| 3 | 4 | 6 | 57 | 2 | 6% |
| 3 | 9 | 6 | 55 | 2 | 6% |
Per Signature Limit of Detection for Rift Valley Fever Strains Tested: All tests were conducted on total nucleic acid extracts from clarified viral cultures containing the listed strains.
| Plaque-forming Units (pfu) | Picograms total RNA | |||||||
| SignatureName | SA75 | Ken 58(B691) | MauritaniaOS-1 | ZH548 | ZH501 | SA51 | MP-12 | |
| Degenerate | SC1 | 0.10 | 1.0 | 0.001 | 100.0 | 1.0 | 0.01 | 0.10 |
| SC2 | 0.10 | 1.0 | 0.001 | 100.0 | 1.0 | 0.10 | 0.10 | |
| M2C2 | 0.10 | 1.0 | 0.001 | 10.0 | 0.10 | 0.01 | 0.10 | |
| L1C1 | 0.001 | 0.10 | 0.001 | 100.0 | 1.0 | 0.001 | 0.10 | |
| L1C2 | 0.01 | 0.10 | 0.01 | 1000.0 | 1.0 | 0.001 | 0.10 | |
| L2C3 | 1.0 | 1.0 | 0.01 | 1000.0 | 1.0 | 1.0 | 1.0 | |
| Non-degenerate | 1756318 | 0.10 | 1.0 | 0.10 | 10.0 | 0.10 | 1000.0 | 0.10 |
| 1756321 | 1.0 | 100.0 | 1.0 | 100.0 | 1.0 | 1000.0 | 1.0 | |
| 1756325 | 0.10 | 1.0 | 0.01 | 10.0 | 0.10 | 1000.0 | 0.10 | |
QRT-PCR tests were performed in triplicate on the ABI7500FAST platform as described in materials and methods. An 8-log dilution series of templates ranging from 200 pfu/ul to 2×10−4 pfu/ul (or 20 pg/ul to 2×10−6 pg/ul for MP-12) was made for each template. Five microliters of each dilution was spiked into qRT-PCR plates in triplicate.
A plaque-forming unit (PFU) is a measure of the number of particles capable of forming plaques per unit volume, such as virus particles. It is a functional measurement rather than a measurement of the absolute quantity of particles: viral particles that are defective or which fail to infect their target cell will not produce a plaque and thus will not be counted.
For RVF MP-12, no titer information is provided as multiple attempts to titer this species failed due to lack of consistent CPE. Thus, sensitivity of this assay is reported in pg of total nucleic acid extract from viral culture. No other RNA (such as poly-A RNA used as carrier in extractions) was spiked into samples. For the degenerate signatures, only the primer/probe combinations that were able to detect all strains of RVFV tested are listed.